Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy

Proteomics - Clinical Applications

Volumn 4, Issue 2, 2010, Pages 143-158

  Scatena, Roberto ^a   Bottoni, Patrizia ^a   Pontoglio, Alessandro ^a   Giardina, Bruno ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cancer cell metabolism; Cancer stem cell; Cancer therapeutics; Mitochondria; Warburg effect

Indexed keywords

6 PHOSPHOFRUCTOKINASE; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE 6 PHOSPHATE ISOMERASE; GLUCOSE TRANSPORTER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE MUTASE; PROTEIN KINASE B; PYRUVATE KINASE; TRIOSEPHOSPHATE ISOMERASE;

BINDING SITE; CANCER CELL; CANCER GROWTH; CELL METABOLISM; CITRIC ACID CYCLE; FUNCTIONAL PROTEOMICS; GLYCOLYSIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; WARBURG EFFECT;

ANIMALS; GLUCOSE; HUMANS; MITOCHONDRIA; NEOPLASMS; PROGNOSIS; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 77951931229     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900157     Document Type: Review

References (141)

1. Gatenby, R. A., Gillies, R. J., Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4, 891-899.
2. Warburg, O., On the origin of cancer cells. Science 1956, 123, 309-314
3. Hammerman, P. S., Fox, C. J., Thompson, C. B., Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem. Sci. 2004, 29, 586-592
4. Moreno-Sanchez, R., Rodriguez-Enriquez, S., Marin-Hernandez, A., Saavedra, E., Energy metabolism in tumor cells. FEBS J. 2007, 274, 1393-1418
5. Kim, J. W., Dang, C. V., Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2007, 66, 8927-8930
6. Garber, K., Energy deregulation: licensing tumor to grow. Science 2006, 312, 1158-1159
7. Kim, J. W., Dang, C. V., Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci. 2005, 30, 142-150
8. Kondoh, H., Lleonart, M. E., Gil, J., Wang, G. et al., Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65, 177-185
9. Gottschalk, S., Anderson, N., Hainz, C. et al., Imatinib (STI571) - mediated changes in glucose metabolism in human leukaemia BCR-ABL-positive cells. Clin. Cancer Res. 2004, 10, 6661-6668
10. Costello, L. C., Franklin, R. B., Why do tumour cells glycolyse from glycolysis?: through citrate to lipogenesis. Mol. Cell Biochem. 2005, 280, 1-8
11. Shaw, R. J., Glucose metabolism and cancer. Curr. Opin. Cell Biol. 2006, 18, 598-608
12. Kroemer, G., Pouyssegur, J., Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13, 472-482
13. Deberardinis, R. J., Sayed, N., Ditsworth, D., Thompson, C. B., Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008, 18, 54-61
14. Wu, N., Zhang, W., Yang, Y., Liang, Y. L. et al., Profilin 1 obtained by proteomic analysis in all-trans retinoic acid-treated hepatocarcinoma cell lines is involved in inhibition of cell proliferation and migration. Proteomics 2006, 6, 6095-6106
15. Bottoni, P., Giardina, B., Vitali, A., Boninsegna, A., Scatena, R., A proteomic approach to characterizing ciglitazone-induced cancer cell differentiation in Hep-G2 cell line. Biochim. Biophys. Acta 2009, 1794, 615-626
16. Denkert, C., Budczies, J., Weichert, W., Wohlgemuth, G. et al., Metabolite profiling of human colon carcinoma deregulation of TCA cycle and amino acid turnover. Mol. Cancer 2008, 7,72
17. Liu, L., Wang, S., Zhang, Q., Ding, Y., Identification of potential genes/proteins regulated by Tiam1 in colorectal cancer by microarray analysis and proteome analysis. Cell Biol. Int. 2008, 32, 1215-1222
18. Byrne, J. C., Downes, M. R., O'Donoghue, N., O'Keane, C. et al., 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J. Proteome Res. 2009, 8, 942-957
19. Bindukumar, B., Schwartz, S., Aalinkeel, R., Mahajan, S. et al., Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells. Prostate 2008, 68, 1531-1545
20. Unwin, R. D., Craven, R. A., Harnden, P., Hanrahan, S. et al., Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003, 3, 1620-1632
21. Perroud, B., Lee, J., Valkova, N., Dhirapong, A. et al., Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol. Cancer 2006, 5, 64.
22. Breton, J., Gage, M. C., Hay, A. W., Keen, J. N. et al., Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldoketo reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma. J. Proteome Res. 2008, 7, 1953-1962
23. Zhou, G., Li, H., Gong, Y., Zhao, Y. et al., Proteomic analysis of global alteration of protein expression in squamous cell carcinoma of the esophagus. Proteomics 2005, 5, 3814-3821
24. Lu, Z. J., Song, Q. F., Jiang, S. S., Song, Q. et al., Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen. Biomed Chromatogr. Cancer 2009, 9,16
25. Zhang, K., Wrzesinski, K., Stephen, J. F., Larsen, P. M. et al., Comparative proteome analysis of three mouse lung adenocarcinoma CMT cell lines with different metastatic potential by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2008, 8, 4932-4945
26. Smith-Beckerman, D. M., Fung, K. W., Williams, K. E., Auersperg, N. et al., Proteome changes in ovarian epithelial cells derived from women with BRCA1 mutations and family histories of cancer. Mol. Cell. Proteomics 2005, 4, 156-168
27. Young, T. W., Mei, F. C., Yang, G., Thompson-Lanza, J. A. et al., Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res. 2004, 64, 4577-4584
28. Martín, B., Sanz, R., Aragüés, R., Oliva, B., Sierra, A., Functional clustering of metastasis proteins describes plastic adaptation resources of breast-cancer cells to new microenvironments. J. Proteome Res. 2008, 7, 3242-3253
29. Goodison, S., Urquidi, V., Breast tumor metastasis: analysis via proteomic profiling. Exp. Rev. Proteomics 2008, 5, 457-467
30. Lee, J. D., Yang, W. I., Park, Y. N., Kim, K. S. et al., Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J. Nucl. Med. 2005, 46, 1753-1759
31. Chen, E. I., Hewel, J., Krueger, J. S., Tiraby, C. et al., Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 2007, 67, 1472-1486
32. Dihal, A. A., van der Woude, H., Hendriksen, P. J., Charif, H. et al., Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics 2008, 8, 45-61
33. Scatena, R., Bottoni, P., Giardina, B., Modulation of cancer cell line differentiation: a neglected proteomic analysis with potential implications in pathophysiology, diagnosis, prognosis, and therapy of cancer. Proteomics Clin. Appl. 2008, 2, 229-237
34. Le Moguen, K., Lincet, H., Marcelo, P., Lemoisson, E. et al., A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment. Proteomics 2007, 7, 4090-4101
35. Vona-Davis, L., Vincent, T., Zulfiqar, S., Jackson, B. et al., Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin. J. Gastrointest. Surg. 2004, 8, 1018-1023
36. van den Bemd, G. J., Krijgsveld, J., Luider, T. M., van Rijswijk, A. L. et al., Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol. Cell. Proteomics 2006, 5, 1830-1839
37. Harris, R. A., in: David, L., Devlin, T. M. (Eds.), Textbook of Biochemistry with Clinical Correlations, 6th Edn., Wiley, Hoboken, NJ 2006, pp. 581-635
38. Mathupala, S. P., Ko, Y. H., Pedersen, P. L., Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25, 4777-4786
39. Pelicano, H., Martin, D. S., Xu, R. H., Huang, P., Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25, 4633-4646
40. Robey, R. B., Hay, N., Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006, 25, 4683-4696
41. Danial, N. N., Gramm, C. F., Scorrano, L., Zhang, C. Y. et al., BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003, 424, 896-897
42. Miller, S., Ross-Inta, C., Giulivi, C., Kinetic and proteomic analyses of S-nitrosoglutathione-treated hexokinase A: consequences for cancer energy metabolism. Amino Acids 2007, 32, 593-602
43. Amadori, D., Frassineti, G. L., De Matteis, A., Mustacchi, G. et al., Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast Cancer Res. Treat. 1998, 49, 209-217
44. Funasaka, T., Hu, H., Hogan, V., Raz, A., Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence. J. Biol. Chem. 2007, 282, 36362-36369
45. Funasaka, T., Hu, H., Yanagawa, T., Raz, A., Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res. 2007, 67, 4236-4243
46. Yuan, Y., Li, W., Li, L., Yang, X et al., Effects of tetrazanbigen on the protein expression in human hepatocellular carcinoma cell line QGY-7701. J. Huazhong Univ. Sci. Technol. Med. Sci. 2009, 29, 304-308
47. Rathmell, J. C., Fox, C. J., Plas, D. R., Hammerman, P. S. et al., Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 2003, 23, 7315-7328
48. Bando, H., Atsum, i T., Nishio, T., Niwa, H. et al., Phosphorylation of the 6-phosphofructo-2-kinase/fructose2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin. Cancer Res. 2005, 11, 5784-5792
49. Deng, H., Yu, F., Chen, J., Zhao, Y. et al., Phosphorylation of Bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1. J. Biol. Chem. 2008, 283, 20754-20760
50. Schapira, F., Resurgence of fetal isozymes in cancer: study of aldolase, pyruvate kinase, lactic dehydrogenase, and beta-hexosaminidase. Isozymes Curr. Top. Biol. Med. Res. 1981, 5, 27-75
51. Wu, C., Luo, Z., Chen, X., Wu, C. et al., Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers. Oncol. Rep. 2009, 21, 1429-1437
52. Bi, X., Lin, Q., Foo, T. W., Joshi, S. et al., Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol. Cell. Proteomics 2006, 5, 1119-1130
53. Kuramitsu, Y., Nakamura, K., Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Exp. Rev. Proteomics 2005, 2, 589-601
54. Stigliano, A., Cerquetti, L., Borro, M., Gentile, G. et al., Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocr. Relat. Cancer 2008, 15, 1-10
55. Li, C., Xiao, Z., Chen, Z., Zhang, X. et al., Proteome analysis of human lung squamous carcinoma. Proteomics 2006, 6, 547-558
56. Khalil, A. A., Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007, 98, 201-213
57. Semenza, G. L., Roth, P. H., Fang, H. M., Wang, G. L., Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994, 269, 23757-23763
58. Semenza, G. L., Jiang, B. H., Leung, S. W., Passantino, R. et al., Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 1996, 271, 32529-32537
59. Ebert, B. L., Gleadle, J. M., O'Rourke, J. F., Bartlett, S. M. et al., Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: similarities with the regulation of erythropoietin. Biochem. J. 1996, 313, 809-814
60. Wang, G. L., Semenza, G. L., Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 1995, 270, 1230-1237
61. Firth, J. D., Ebert, B. L., Pugh, C. W., Ratcliffe, P. J., Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer. Proc. Natl. Acad. Sci. USA 1994, 91, 6496-6500
62. Graven, K. K., Yu, Q., Pan, D., Roncarati, J. S., Farber, H. W., Identification of an oxygen responsive enhancer element in the glyceraldehyde-3-phosphate dehydrogenase gene. Biochim. Biophys. Acta 1999, 1447, 208-218
63. Shadidi, M., Sørensen, D., Dybwad, A., Furset, G., Sioud, M., Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma. Int. J. Oncol. 2008, 32, 241-247
64. Zou, L., Wu, Y., Pei, L., Zhong, D. et al., Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis. Leuk. Res. 2005, 29, 1387-1391
65. He, Q. Y., Cheung, Y. H., Leung, S. Y., Yuen, S. T. et al., Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 2004, 4, 3276-3287
66. Mikuriya, K., Kuramitsu, Y., Ryozawa, S., Fujimoto, M. et al., Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int. J. Oncol. 2007, 30, 849-855
67. Takashima, M., Kuramitsu, Y., Yokoyama, Y., Iizuka, N. et al., Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics 2004, 3, 2487-2493
68. Kovarova, H., Hajduch, M., Korinkova, G., Halada, P. et al., Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis 2000, 21, 3757-3764
69. Zhang, D., Tai, L. K., Wong, L. L., Chiu, L. L. et al., Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 2005, 4, 1686-1696
70. Ismail, S. A., Park, H. W., Structural analysis of human liver glyceraldehyde-3-phosphate dehydrogenase. Acta Crystallogr. D Biol. Crystallogr. 2005, 61, 1508-1513
71. Lin, S. J., Guarente, L., Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr. Opin. Cell Biol. 2003, 15, 241-246
72. Sundararaj, K. P., Wood, R. E., Ponnusamy, S., Salas, A. M. et al., Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 2004, 279, 6152-6162
73. Chen, Z., Lu, W., Garcia-Prieto, C., Huang, P., The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr. 2007, 39, 267-274
74. Colell, A., Ricci, J. E., Tait, S., Milasta, S. et al., GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007, 129, 983-997
75. Song, S., Finkel, T., GAPDH and the search for alternative energy. Nat. Cell. Biol. 2007, 9, 869-870
76. Giusti, L., Iacconi, P., Ciregia, F., Giannaccini, G. et al., Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J. Proteome Res. 2008, 7, 4079-4088
77. Sun, W., Xing, B., Sun, Y., Du, X. et al., Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell. Proteomics 2007, 6, 1798-1808
78. Vorum, H., Østergaard, M., Hensechke, P., Enghild, J. J. et al., Proteomic analysis of hyperoxia-induced responses in the human choriocarcinoma cell line JEG-3. Proteomics 2004, 4, 861-867
79. Chen, G., Gharib, T.G., Wang, H., Huang, C.C. et al., Protein profiles associated with survival in lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2003, 100, 13537-13542
80. Narasimhan, K., Changqing, Z., Choolani, M., Ovarian cancer proteomics: many technologies one goal. Proteomics Clin. Appl. 2008, 2, 195-218
81. Thierolf, M., Hagmann, M. L., Pfeffer, M., Berntenis, N. et al., Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin. Appl. 2008, 2, 11-22
82. Lay, A. J., Jiang, X. M., Kisker, O., Flynn, E. et al., Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature 2000, 408, 869-873
83. Daly, E. B., Wind, T., Jiang, X. M., Sun, L. et al., Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochim. Biophys. Acta 2004, 1691, 17-22
84. Hwang, T. L., Liang, Y., Chien, K. Y., Yu, J. S., Over-expression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 2006, 6, 2259-2272
85. Jang, C. H., Lee, I. A., Ha, Y. R., Lim, J. et al., PGK1 induction by a hydrogen peroxide treatment is suppressed by antioxidants in human colon carcinoma cells. Biosci. Biotechnol. Biochem. 2008, 72, 1799-1808
86. Chuthapisith, S., Layfield, R., Kerr, I. D., Hughes, C., Eremin, O., Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int. J. Oncol. 2007, 30, 1545-1551
87. Fothergill, L. A., Herman, C., Watson, T. I., The phosphoglycerate mutases. Adv. Enzymol. Mol. Biol. 2006, 62, 213-227
88. Turhani, D., Krapfenbauer, K., Thurnher, D., Langen, H., Fountoulakis, M., Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 2006, 27, 1417-1423
89. Zhang, X., Xiao, Z., Chen, Z., Li, C. et al., Comparative proteomics analysis of the proteins associated with laryngeal carcinoma-related gene 1. Laryngoscope 2006, 116, 224-230
90. Evans, M. J., Saghatelian, A., Sorensen, E. J., Cravatt, B. F., Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat. Biotechnol. 2005, 23, 1303-1307
91. Narayanan, N. K., Narayanan, B. A., Nixon, D. W., Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detect. Prev. 2004, 28, 443-452
92. Pancholi, V., Multifunctional alpha-enolase: its role in diseases. Cell Mol. Life Sci. 2001, 58, 902-920
93. Altenberg, B., Greulich, K. O., Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84, 1014-1020
94. He, P., Naka, T., Serada, S., Fujimoto, M. et al., Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci. 2007, 98, 1234-1240
95. Rütters, H., Zürbig, P., Halter, R., Borlak, J., Towards a lung adenocarcinoma proteome map: studies with SP-C/c-raf transgenic mice. Proteomics 2006, 6, 3127-3137
96. Chung, J. C., Oh, M. J., Choi, S. H., Bae, C. D., Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J. Surg. 2008, 78, 245-251
97. Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Mikuria, K. et al., Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 2007, 31, 1345-1350
98. Dai, Z., Fan, J., Liu, Y., Zhou, J. et al., Identification and analysis of alpha1,6-fucosylated proteins in human normal liver tissues by a target glycoproteomic approach. Electrophoresis 2007, 28, 4382-4391
99. Schulz, D. M., Bollner, C., Thomas, G., Atkinson, M. et al., Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J. Proteome Res. 2009, 8, 3430-3438
100. Khalil, A. A., Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007, 98, 201-213
101. Yi, Z., Jingting, C., Yu, Z., Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells. Int. J. Gynecol. Cancer 2009, 19, 326-333
102. Wong, C. S., Wong, V. W., Chan, C. M., Ma, B. B. et al., Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol. Rep. 2008, 20, 89-98
103. Mazurek, S., Boschek, C. B., Hugo, F., Eigenbrodt, E., Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15, 300-308
104. Du, X. L., Hu, H., Lin, D. C., Xia, S. H. et al., Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J. Mol. Med. 2007, 85, 863-875
105. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., Cantley, L. C., Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452, 181-186
106. Fantin, V. R., St-Pierre, J., Leder, P., Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9, 425-434
107. Hilf, R., Rector, W. D., Orlando, R. A., Multiple molecular forms of lactate dehydrogenase and glucose 6-phosphate dehydrogenase in normal and abnormal human breast tissues. Cancer 1976, 37, 1825-1830
108. Leiblich, A., Cross, S. S., Catto, J. W., Phillips, J. T. et al., Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene 2006, 25, 2953-2960
109. Glen, A., Gan, C. S., Hamdy, F. C., Eaton, C. L. et al., iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J. Proteome Res. 2008, 7, 897-907
110. Ding, S. J., Li, Y., Shao, X. X., Zhou, H. et al., Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics 2004, 4, 982-994
111. Koukourakis, M. I., Giatromanolaki, A., Harris, A. L., Sivridis, E., Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006, 66, 632-637
112. Balinsky, D., Platz, C. E., Lewis, J. W., Isozyme patterns of normal, benign, and malignant human breast tissues. Cancer Res. 1983, 43, 5895-5901
113. Kawamoto, M., Breast cancer diagnosis by lactate dehydrogenase isozymes in nipple discharge. Cancer 1994, 73, 1836-1841
114. Koukourakis, M. I., Giatromanolaki, A., Simopoulos, C., Polychronidis, A., Sivridis, E., Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin. Exp. Metastasis 2005, 22, 25-30
115. Koukourakis, M. I., Giatromanolaki, A., Polychronidis, A., Simopoulos, C. et al., Endogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer. Cancer Sci. 2006, 97, 582-588
116. Jones, R. G., Thompson, C. B., Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009, 23, 537-548
117. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., Thompson, C. B., The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7, 11-20
118. Bui, T., Thompson, C. B., Cancer's sweet tooth. Cancer Cell 2006, 9, 419-420
119. López-Ríos, F., Sánchez-Aragó, M., García-García, E., Ortega, A. D. et al., Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res. 2007, 67, 9013-9017
120. Dihal, A. A., van der Woude, H., Hendriksen, P. J., Charif, H. et al., Transcriptome and proteome profiling of colon mucosa from quercetin fed F344 rats point to tumor preventive mechanisms, increased mitochondrial fatty acid degradation and decreased glycolysis. Proteomics 2008, 8, 45-61
121. Isidoro, A., Casado, E., Redondo, A., Acebo, P. et al., Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005, 26, 2095-2104
122. Mazzanti, R., Solazzo, M., Fantappié, O., Elfering, S. et al., Differential expression proteomics of human colon cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G1329-G1338
123. Kaelin Jr W. G., Ratcliffe, P. J., Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30, 393-402
124. 2 availability on human cancer. Nat. Rev. Cancer 2008, 8, 967-975
125. Scatena, R., Bottoni, P., Giardina, B., in: Singh, K. K., Costello, L. (Eds.), Mitochondria and Cancer, Springer, Philadelphia, USA 2008, pp. 93-102
126. Vaupel, P., The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9, 10-17
127. Semenza, G. L., Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 2009, 19, 12-16
128. Hsu, P. P., Sabatini, D. M., Cancer cell metabolism: Warburg and beyond. Cell 2008 134, 703-707
129. Denko, N. C., Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 2008, 8, 705-713
130. Vander Heiden, M. G., Cantley, L. C., Thompson, C. B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324, 1029-1033
131. Semenza, G. L., Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem. J. 2007, 405, 1-9
132. Kimbro, K. S., Simons, J. W., Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer 2006, 13, 739-749
133. Liu, R., Li, Z., Bai, S., Zhang, H., Tang, M. et al., Mechanism of cancer cell adaptation to metabolic stress: proteomics identification of a novel thyroid hormone-mediated gastric carcinogenic signaling pathway. Mol. Cell. Proteomics 2009, 8, 70-85
134. Frezza, C., Gottlieb, E., Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 2009, 19, 4-11
135. Samuels, Y., Ericson, K., Oncogenic PI3 K and its role in cancer. Curr. Opin. Oncol. 2006, 18, 77-82
136. Lagadec, C., Meignan, S., Adriaenssens, E., Foveau, B. et al., TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009, 28, 1960-1970
137. Ahn, Y., Hwang, C. Y., Lee, S. R., Kwon, K. S., Lee, C., The tumour suppressor PTEN mediates a negative regulation of the E3 ubiquitin-protein ligase Nedd4. Biochem. J. 2008, 412, 331-338
138. Skvortsova, I., Skvortsov, S., Stasyk, T., Raju, U. et al., Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008, 8, 4521-4533
139. Hegde, P. S., Rusnak, D., Bertiaux, M., Alligood, K. et al., Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol. Cancer Ther. 2007, 6, 1629-1640
140. Bottoni, P., Giardina, B., Scatena, R., Proteomic profiling of heat shock proteins: an emerging molecular approach with direct pathophysiological and clinical implications. Proteomics Clin. Appl. 2009, 3, 636-653
141. Scatena, R., Bottoni, P., Pontoglio, A., Mastrototaro, L., Giardina, B., Glycolytic enzyme inhibitors in cancer treatment. Exp. Opin. Investig. Drugs 2008, 17, 1533-1545